US Patent

US9687571 — Stabilization of radiopharmaceutical compositions using ascorbic acid

Method of Use · Assigned to Lantheus Medical Imaging Inc · Expires 2032-11-01 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of stabilizing radiopharmaceutical compositions using ascorbic acid to maintain a pH within the range of 3.5-5.5.

USPTO Abstract

Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4011`	—

Patent Metadata

Patent number: US9687571
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Lantheus Medical Imaging Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.